Plant Name: Vigna umbeuata
Taxonomic Information:
Plant ID: NPO18224
Plant Latin Name: Vigna umbeuata
Taxonomy Genus: Vigna
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| ALPL; TDP1; PIK3CA; PIK3CB; ALOX12; HSD17B10; NQO2; NOX4; POLB; | |
| ACHE; | |
| PIM1; MET; AXL; FLT3; CDK1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA9; CA14; CA7; | |
| ESR1; | |
| PTGS2; | |
| NFKB1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.890E-11 | 2.104E-07 | CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.625E-09 | 1.110E-05 | CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.690E-07 | 2.092E-04 | CA12, CA2, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 3.750E-07 | 2.478E-04 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, NFKB1, PIK3CA, PIM1, PTGS2 |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 5.531E-07 | 3.346E-04 | IGF1R, PIK3CA, PIK3CB |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.737E-07 | 3.762E-04 | CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 8.754E-07 | 4.649E-04 | ALPL, CYP1B1, ESR1, FLT3, NFKB1, NOX4, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.474E-06 | 5.944E-04 | CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 2.316E-06 | 8.266E-04 | ACHE, ALOX12, ALPL, AXL, CA12, CA14, CA2, CA9, ESR1, FLT3, HSD17B10, IGF1R, KDR, MET, NPSR1, PIK3CA, PIK3CB, PIM1, TDP1 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.434E-06 | 1.187E-03 | AXL, MET, NOX4, PIK3CA, PIK3CB |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 3.640E-06 | 1.238E-03 | AXL, NFKB1, NOX4, PIK3CA, PIK3CB, POLB, PTGS2 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.519E-06 | 1.491E-03 | AXL, KDR, PIK3CA, PIK3CB |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 5.408E-06 | 1.707E-03 | AXL, CA2, CDK1, CYP1A2, CYP1B1, KDR, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.863E-06 | 1.824E-03 | CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.989E-06 | 2.114E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 9.195E-06 | 2.534E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.185E-05 | 3.072E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.396E-05 | 3.455E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 1.807E-05 | 4.231E-03 | ALOX12, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.615E-05 | 5.932E-03 | AURKB, CDK1, NOX4, POLB, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.801E-05 | 6.224E-03 | CYP1A2, CYP1B1, CYP3A4, NQO2 |
| BP | GO:0008152; metabolic process | GO:0030258; lipid modification | 3.333E-05 | 7.257E-03 | ALOX12, CYP3A4, MET, PIK3CA, PIK3CB |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.484E-05 | 7.416E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 4.547E-05 | 9.254E-03 | ALOX12, CDK1, ESR1, FLT3, IGF1R, KDR, PIM1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 4.873E-05 | 9.370E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.810E-05 | 9.370E-03 | AURKB, AXL, CDK1, FLT3, IGF1R, KDR, MET, PIK3CA, PIK3CB, PIM1 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 4.873E-05 | 9.370E-03 | FLT3, KDR |
| MF | GO:0003824; catalytic activity | GO:0035005; 1-phosphatidylinositol-4-phosphate 3-kinase activity | 4.873E-05 | 9.370E-03 | PIK3CA, PIK3CB |
| BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 5.094E-05 | 9.563E-03 | CA2, CA7, ESR1, NOX4, NPSR1, PIK3CA, PIK3CB |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 5.169E-05 | 9.620E-03 | ALOX12, IGF1R, KDR, MET, NOX4, PTGS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.267E-11 | 4.280E-09 | CA12, CA2, CA7, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.121E-08 | 1.389E-06 | PIK3CA, FLT3, PIM1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.922E-07 | 2.149E-05 | PIK3CA, KDR, PIK3CB, ESR1, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 9.461E-07 | 3.099E-05 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.581E-06 | 4.142E-05 | PIK3CA, FLT3, PIK3CB, PTGS2, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.022E-06 | 4.415E-05 | PIK3CA, KDR, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 3.726E-06 | 5.737E-05 | PIK3CA, PIK3CB, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.952E-06 | 5.524E-05 | PIK3CA, FLT3, PIK3CB, MET |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 3.941E-06 | 5.737E-05 | PIK3CA, PIK3CB, ESR1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.485E-06 | 5.875E-05 | PIK3CA, PIM1, CYP1B1, PTGS2, MET, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 9.880E-06 | 9.245E-05 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.190E-06 | 9.245E-05 | PIK3CA, PIK3CB, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 8.018E-06 | 8.753E-05 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.246E-05 | 9.605E-05 | POLB, PIK3CA, CDK1, PIK3CB, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.161E-05 | 9.503E-05 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.142E-05 | 9.503E-05 | PIK3CA, PIK3CB, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.518E-05 | 9.941E-05 | PIK3CA, PIM1, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.433E-05 | 9.879E-05 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.631E-06 | 7.897E-05 | CYP1A2, CYP1B1, CYP3A4, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.347E-05 | 9.803E-05 | PIK3CA, CDK1, PIK3CB, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 2.126E-05 | 1.266E-04 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.640E-05 | 1.023E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.249E-04 | 5.906E-04 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 8.001E-05 | 4.367E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.692E-05 | 3.242E-04 | CYP1B1, PTGS2, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.193E-04 | 5.906E-04 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.448E-04 | 6.324E-04 | FLT3, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 2.253E-04 | 8.433E-04 | PIK3CA, CDK1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.308E-04 | 5.906E-04 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.765E-04 | 7.005E-04 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.308E-04 | 5.906E-04 | PIK3CA, PIK3CB, MET |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.208E-04 | 1.531E-03 | PIK3CA, ALOX12, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.765E-04 | 7.005E-04 | PIK3CA, PIK3CB, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.888E-05 | 4.657E-04 | CYP1A2, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.765E-04 | 7.005E-04 | CYP1A2, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 4.335E-04 | 1.535E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 5.694E-04 | 1.750E-03 | POLB, PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 4.464E-04 | 1.539E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 2.148E-04 | 8.274E-04 | PIK3CA, PIK3CB, MET |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 5.007E-04 | 1.640E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 6.056E-04 | 1.803E-03 | ACHE, PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 5.294E-04 | 1.691E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 5.007E-04 | 1.640E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 5.743E-04 | 1.750E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 7.236E-04 | 2.061E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 7.236E-04 | 2.061E-03 | PIK3CA, PIK3CB, ESR1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 7.598E-04 | 2.074E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 7.598E-04 | 2.074E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 8.357E-04 | 2.234E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 1.001E-03 | 2.530E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.187E-03 | 2.827E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.024E-03 | 2.530E-03 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.092E-03 | 2.648E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.024E-03 | 2.530E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.339E-03 | 3.077E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 1.475E-03 | 3.331E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.236E-03 | 2.892E-03 | PIK3CA, PIK3CB, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 1.679E-03 | 3.548E-03 | PIK3CA, PIM1, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.679E-03 | 3.548E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 2.247E-03 | 4.600E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 2.712E-03 | 5.382E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.232E-03 | 6.136E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 4.659E-03 | 8.139E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 3.647E-03 | 6.826E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 5.350E-03 | 8.872E-03 | PTGS2, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.659E-03 | 8.139E-03 | MET, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.494E-03 | 8.996E-03 | MET, IGF1R |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 5.069E-03 | 8.513E-03 | CA2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.266E-03 | 7.656E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.794E-03 | 8.264E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 3.890E-03 | 7.077E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 3.185E-03 | 6.136E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 2.753E-03 | 5.382E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.890E-03 | 7.077E-03 | ALOX12, PTGS2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 2.351E-03 | 4.737E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 2.069E-03 | 4.302E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.557E-03 | 3.457E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.638E-03 | 3.548E-03 | CYP1A2, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 8.611E-04 | 2.256E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; PIK3CB; CA9; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; NQO2; CA9; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; NFKB1; FLT3; ACHE; PTGS2; PIK3CB; NQO2; CA9; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
